Medscape

FDA Clears Subcutaneous Methotrexate Injection (Rasuvo)

The US Food and Drug Administration (FDA) has approved a subcutaneous injectable methotrexate delivered in an auto-injector (Rasuvo, Medac Pharma) for rheumatoid arthritis (RA), polyarticular-course ...
Medindia

Medac Pharma, Inc. Secures FDA Approval of Trade Name Rasuvo™ for Lead Methotrexate Subcutaneous Injectable Product

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug ...
Monthly Prescribing Reference

Rasuvo Autoinjector Launched for RA, pJIA, Psoriasis

FDA to Review MPI-2505 NDA for RA, Psoriasis Medac Pharma announced the launch of Rasuvo (methotrexate) injection for patients with rheumatoid arthritis, polyarticular course juvenile idiopathic ...
Monthly Prescribing Reference

FDA Approves Rasuvo Injection for RA, JIA, Psoriasis

FDA to Review MPI-2505 NDA for RA, Psoriasis Medac Pharma announced that the FDA has approved Rasuvo (methotrexate) subcutaneous auto-injector for the management of rheumatoid arthritis, polyarticular ...
Pharmabiz

US FDA approves Medac Pharma's Rasuvo injection for RA, pJIA & psoriasis

The US Food and Drug Administration (FDA) has approved Medac Pharma's Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), ...
MM&M

Medac hires HCB to promote RA drug

Medac Pharma hired HCB Health as AOR for Rasuvo, an injectable drug used to treat patients with rheumatoid arthritis and psoriasis. The firm is tasked with developing professional digital media and ...
Business Wire

Koios Pharmaceuticals Receives Favorable Ruling in Challenge to High-Cost Drug’s Patent

SANTA MONICA, Calif.--(BUSINESS WIRE)--In response to a petition from Koios Pharmaceuticals LLC, the United States Patent and Trademark Office (“PTO”) has instituted inter partes review of the sole ...